Evidence map›Paper›PMID 22058220›Full record

Trial reportHaematologica2012

Telomere length is associated with disease severity and declines with age in dyskeratosis congenita.

Blanche P Alter, Philip S Rosenberg, Neelam Giri, Gabriela M Baerlocher, Peter M Lansdorp, Sharon A Savage

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Haematologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00027274 (Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes), which is not on this map. Cited by 142 papers.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00027274 recruitingnot on this map

Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2001Enrolled4,000ConditionsDiamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome
3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 232 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Danazol Treatment for Telomere Diseases.The New England journal of medicine · 2016
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Blanche P AlterClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852-7231, USA. alterb@mail.nih.gov
Philip S Rosenberg
Neelam Giri
Gabriela M Baerlocher
Peter M Lansdorp
Sharon A Savage
National Institutes of Health · USDepartment of Health and Human Services · USNational Cancer Institute · USUniversity Hospital of Bern · CHUniversity of British Columbia · CA

Funding

Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesZIACP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$111.8M
Chromatin maintenance and sister chromatid differentiationR01GM094146 · NIGMS · BRITISH COLUMBIA CANCER AGENCY · PI LANSDORP, PETER M · 2010 to 2013
$929k
CASE-CONTROL STUDY OF BRAIN CANCER AND OCCUPATIONN01CP011019 · CP · ABT ASSOCIATES, INC. · PI STONER, DIANE · 1985 to 1986
–
CIHR RMF-92093Intramural NIH HHSNCI NIH HHS N02 CP011019NCI NIH HHS N02-CP-91026NIGMS NIH HHS R01 GM094146NIGMS NIH HHS R01GM094146PHS HHS HHSN261200655001CPHS HHS RMF-92093
6 · The paper itself

Abstract

backgroundDyskeratosis congenita is a cancer-prone bone marrow failure syndrome caused by aberrations in telomere biology. DESIGN AND

methodsWe studied 65 patients with dyskeratosis congenita and 127 unaffected relatives. Telomere length was measured by automated multicolor flow fluorescence in situ hybridization in peripheral blood leukocyte subsets. We age-adjusted telomere length using Z-scores (standard deviations from the mean for age).

resultsWe confirmed that telomere lengths below the first percentile for age are very sensitive and specific for the diagnosis of dyskeratosis congenita. We provide evidence that lymphocytes alone and not granulocytes may suffice for clinical screening, while lymphocyte subsets may be required for challenging cases, including identification of silent carriers. We show for the first time using flow fluorescence in situ hybridization that the shortest telomeres are associated with severe variants (Hoyeraal-Hreidarsson and Revesz syndromes), mutations in DKC1, TINF2, or unknown genes, and moderate or severe aplastic anemia. In the first longitudinal follow up of dyskeratosis congenita patients, we demonstrate that telomere lengths decline with age, in contrast to the apparent stable telomere length observed in cross-sectional data.

conclusionsTelomere length by flow fluorescence in situ hybridization is an important diagnostic test for dyskeratosis congenita; age-adjusted values provide a quantitative measure of disease severity (clinical subset, mutated gene, and degree of bone marrow failure). Patients with dyskeratosis congenita have accelerated telomere shortening. This study is registered at www.clinicaltrials.gov (identifier: NCT00027274).

Indexed as

Telomere ShorteningAdolescentAdultAgedAge FactorsAgingChildChild, PreschoolDisease ProgressionDyskeratosis CongenitaFemaleHumansInfantInfant, NewbornLongitudinal StudiesMale

Identifiers

PMID22058220
PMCPMC3291588
OpenAlexW1994932701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.